Susquehanna International Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-322,900
| Closed | -$32.9M | – | 13348 |
|
|
2023
Q2 | $32.9M | Sell |
322,900
-114,300
| -26% | -$10.8M | 0.01% | 1289 |
|
|
2023
Q1 | $39.8M | Buy |
437,200
+183,600
| +72% | +$10.8M | 0.01% | 1097 |
|
|
2022
Q4 | $9.63M | Buy |
253,600
+80,900
| +47% | +$2.78M | ﹤0.01% | 2319 |
|
|
2022
Q3 | $4.34M | Buy |
172,700
+73,600
| +74% | +$2.04M | ﹤0.01% | 3397 |
|
|
2022
Q2 | $3.01M | Sell |
99,100
-172,200
| -63% | -$5.14M | ﹤0.01% | 4073 |
|
|
2022
Q1 | $8.89M | Buy |
271,300
+196,100
| +261% | +$5.82M | ﹤0.01% | 2708 |
|
|
2021
Q4 | $1.98M | Buy |
75,200
+12,400
| +20% | +$960K | ﹤0.01% | 5529 |
|
|
2021
Q3 | $6.32M | Buy |
62,800
+26,700
| +74% | +$3.13M | ﹤0.01% | 3558 |
|
|
2021
Q2 | $5.11M | Sell |
36,100
-92,200
| -72% | -$10.4M | ﹤0.01% | 4000 |
|
|
2021
Q1 | $12.8M | Buy |
128,300
+26,400
| +26% | +$3.08M | ﹤0.01% | 2417 |
|
|
2020
Q4 | $12.6M | Buy |
101,900
+26,300
| +35% | +$3.46M | ﹤0.01% | 2229 |
|
|
2020
Q3 | $7.37M | Sell |
75,600
-22,500
| -23% | -$2.81M | ﹤0.01% | 2581 |
|
|
2020
Q2 | $15.3M | Sell |
98,100
-11,400
| -10% | -$1.73M | ﹤0.01% | 1683 |
|
|
2020
Q1 | $15.8M | Buy |
109,500
+33,700
| +44% | +$6.51M | 0.01% | 1352 |
|
|
2019
Q4 | $15.5M | Sell |
75,800
-9,000
| -11% | -$1.64M | ﹤0.01% | 1660 |
|
|
2019
Q3 | $6.81M | Buy |
84,800
+43,600
| +106% | +$3.7M | ﹤0.01% | 2359 |
|
|
2019
Q2 | $3.89M | Sell |
41,200
-36,200
| -47% | -$3.13M | ﹤0.01% | 3070 |
|
|
2019
Q1 | $6.62M | Buy |
77,400
+51,600
| +200% | +$4.28M | ﹤0.01% | 2144 |
|
|
2018
Q4 | $1.45M | Sell |
25,800
-38,100
| -60% | -$2.33M | ﹤0.01% | 4037 |
|
|
2018
Q3 | $5.22M | Buy |
63,900
+34,900
| +120% | +$2.46M | ﹤0.01% | 2643 |
|
|
2018
Q2 | $1.01M | Buy |
29,000
+16,400
| +130% | +$499K | ﹤0.01% | 5329 |
|
|
2018
Q1 | $258K | Buy |
+12,600
| New | +$324K | ﹤0.01% | 7879 |
|
|
2017
Q4 | – | Sell |
-12,100
| Closed | -$376K | – | 10088 |
|
|
2017
Q3 | $376K | Buy |
+12,100
| New | +$364K | ﹤0.01% | 7024 |
|
Other funds holding RETA
Susquehanna International Group's RETA Position: Q3 2023 in Review
Susquehanna International Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 84,059 shares — an estimated $8.57M sold.
Susquehanna International Group first reported a position in RETA in Q2 2019 and held it in 14 quarters. The position peaked at $13M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Susquehanna International Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Susquehanna International Group sold 84,059 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.57M.
- Susquehanna International Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 14 quarters.
- Susquehanna International Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $13M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.